Altimmune, Inc.
ALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $20 | $426 | -$68 | $4,410 |
| % Growth | -95.3% | 726.5% | -101.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $20 | $426 | -$68 | $4,410 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $82,226 | $65,799 | $70,538 | $74,541 |
| G&A Expenses | $20,966 | $18,137 | $17,134 | $15,413 |
| SG&A Expenses | $20,966 | $18,137 | $17,134 | $15,413 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $12,419 | $0 | $11,370 |
| Operating Expenses | $103,192 | $96,355 | $87,672 | $101,324 |
| Operating Income | -$103,172 | -$95,929 | -$87,740 | -$96,914 |
| % Margin | -515,860% | -22,518.5% | 129,029.4% | -2,197.6% |
| Other Income/Exp. Net | $8,113 | $7,482 | $2,830 | -$176 |
| Pre-Tax Income | -$95,059 | -$88,447 | -$84,910 | -$97,090 |
| Tax Expense | $0 | $0 | -$197 | $0 |
| Net Income | -$95,059 | -$88,447 | -$84,713 | -$97,090 |
| % Margin | -475,295% | -20,762.2% | 124,577.9% | -2,201.6% |
| EPS | -1.34 | -1.66 | -1.81 | -2.35 |
| % Growth | 19.3% | 8.3% | 23% | – |
| EPS Diluted | -1.34 | -1.66 | -1.81 | -2.35 |
| Weighted Avg Shares Out | 71,003 | 53,247 | 46,926 | 41,283 |
| Weighted Avg Shares Out Dil | 71,003 | 53,247 | 46,926 | 41,283 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,074 | $7,351 | $2,870 | $203 |
| Interest Expense | $9 | $35 | $8 | $5 |
| Depreciation & Amortization | $238 | $477 | $493 | $551 |
| EBITDA | -$94,812 | -$87,935 | -$84,409 | -$96,534 |
| % Margin | -474,060% | -20,642% | 124,130.9% | -2,189% |